Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.

CONCLUSION: PCSK9-I treatment increased VLDL size (estimated by an increased VLDL-TG/apoB ratio) and reduced VLDL-associated apolipoproteins in a heterogeneous "real-world" study-population, reflecting a higher clearance of small atherogenic VLDL remnant particles by PCSK9-I. This may potentially lower cardiovascular risk in clinical routine patients beyond low-density cholesterol (LDL-C) reduction.
PMID: 30910670 [PubMed - as supplied by publisher]

Source: Vascular Pharmacology - March 21, 2019 Category: Drugs & Pharmacology Authors: Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U Tags: Vascul Pharmacol Source Type: research